Women’s health landscape shifting, but systemic hurdles remain
It is no secret that research and development (R&D) efforts to improve care in women’s health have long been critically…
08 Oct 2026
Podcast: Key takeaways from EASD 2026 on where GLP-1s are headed
The world of diabetes and obesity research has exploded in recent years with the blockbuster success of glucagon-like peptide (GLP)-1 therapies and the rapid pace of innovation seen with next-generation…
05 Oct 2026
GLP-1RA non-responders: tackling a hidden challenge behind the obesity epidemic
In recent years, the notoriety and uptake of incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) has skyrocketed, with drugs in this class making waves in both the public…
02 Oct 2026
Magazine: Keep it cool
Pharma is being pulled in every direction at once: more complex, more connected, more uncertain. Yet the industry keeps moving, and its momentum shows no sign of slowing. In this…
24 Sep 2026
Podcast: How Sandoz plans to harness its “golden decade”
At its Capital Markets Day on 8 September, Sandoz revealed a new set of targets – part of a roadmap dubbed Bio100 – that could help it become the undisputed…
17 Sep 2026
The shrinking return on investment for Nordic innovation
Despite the region’s reputation as a thriving hub of innovation, Nordic biotechs are having a hard time funding the jump to commercialisation, and experts say there is a risk the…
11 Sep 2026
Staunch biotech competition spurs new secretive tactics, shifts investor approach
In recent years, the pharma and biotech landscape has experienced several seismic geopolitical and technological shifts, including China’s rise to fame in the innovative medicines space and the advent of…